iScience, Volume *26*

Supplemental information

PAK1 contributes to cerebral ischemia/reperfusion injury by regulating the blood-brain barrier integrity

Ming Huang, Jinshun Zhang, Mengwei Li, Haowei Cao, Qiuju Zhu, and Dejun Yang



Figure S1. Immunostaining by different PAK1 antibodies, Related to Figure 1. No primary antibody was used as negative control. PAK1 (CST, Cat#2602; AB_330222, 1:50) is invalidity in immunostaining, relatively PAK1 (Abclonal, Cat#A19608; AB_2862697, 1:50) can effectively display PAK1 expression on microvessels. DyLight 594-conjugated lectins (1:200) were used to show microvessels. Scale bar = 20 μm.



Figure S2. Cell viability of bEnd.3 cells were not altered after OGD/R, Related to Figure 2. Cell viability was measured by CCK-8 assay. OGD 2h and reoxygenation 3h (A)or 24h (B) didn't alter bEnd.3 cell survival, and neither did Frax486 or IPA-3 treatment. Data are expressed as mean ± SEM（n=8）.